MSF asks Johnson & Johnson to step away from secondary patents for key TB drug

Medical charity Medecins Sans Frontieres (MSF) has once again urged Johnson& Johnson (J&J) to not enforce any 'secondary' patents for its tuberculosis drug bedaquiline in any country with a high burden of TB, and withdraw all pending secondary patent applications for it.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news